Our clinical development plan has two main objectives. The primary objective is to obtain evidence of safety and biological activity in a Phase I trial. This is delivered by intratumoural administration in patients with advanced solid tumours (refractory to other available treatments) amenable for direct injection and clinical measurement (head and neck, pancreatic, colorectal, melanoma, lung, breast and other metastatic injectable tumours).

The second objective is to enter Ixovex-1 into a Late Phase Clinical trial and to expand into a commercially valuable new treatment area.